Tags

Type your tag names separated by a space and hit enter

Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
Blood Purif. 2013; 36(1):12-6.BP

Abstract

Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients.

Authors+Show Affiliations

Department of Nephrology and Dialysis, Azienda Ospedaliera Sant'Anna, Como, Italy. antonio.bellasi@hsacomo.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23736115

Citation

Bellasi, Antonio, et al. "Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice." Blood Purification, vol. 36, no. 1, 2013, pp. 12-6.
Bellasi A, Galassi A, Salvi P, et al. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. Blood Purif. 2013;36(1):12-6.
Bellasi, A., Galassi, A., Salvi, P., & Cozzolino, M. (2013). Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. Blood Purification, 36(1), 12-6. https://doi.org/10.1159/000350579
Bellasi A, et al. Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice. Blood Purif. 2013;36(1):12-6. PubMed PMID: 23736115.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. AU - Bellasi,Antonio, AU - Galassi,Andrea, AU - Salvi,Paolo, AU - Cozzolino,Mario, Y1 - 2013/05/25/ PY - 2013/6/6/entrez PY - 2013/6/6/pubmed PY - 2014/1/25/medline SP - 12 EP - 6 JF - Blood purification JO - Blood Purif VL - 36 IS - 1 N2 - Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients. SN - 1421-9735 UR - https://www.unboundmedicine.com/medline/citation/23736115/Paricalcitol_and_cardiorenal_outcome:_from_the_IMPACT_study_to_clinical_practice_ L2 - https://www.karger.com?DOI=10.1159/000350579 DB - PRIME DP - Unbound Medicine ER -